Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
3.240
0.00 (0.00%)
Nov 4, 2024, 4:00 PM EST - Market closed

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
3.43.924.665.664.134.2
Upgrade
Research & Development
2.853.571327.2226.0818.18
Upgrade
Operating Expenses
6.247.4917.6532.8830.2122.38
Upgrade
Operating Income
-6.24-7.49-17.65-32.88-30.21-22.38
Upgrade
Interest & Investment Income
0.190.380.30.561.191.95
Upgrade
Currency Exchange Gain (Loss)
-0.04-0.040.04-0.03-0.12-0.11
Upgrade
Other Non Operating Income (Expenses)
-0.01-0.01-0.02-0.04-0.03-0.03
Upgrade
EBT Excluding Unusual Items
-6.1-7.16-17.34-32.39-29.17-20.57
Upgrade
Gain (Loss) on Sale of Investments
0.220.25-0.53-0.080.40.11
Upgrade
Pretax Income
-5.88-6.91-17.87-32.47-28.77-20.46
Upgrade
Net Income
-5.88-6.91-17.87-32.47-28.77-20.46
Upgrade
Net Income to Common
-5.88-6.91-17.87-32.47-28.77-20.46
Upgrade
Shares Outstanding (Basic)
000000
Upgrade
Shares Outstanding (Diluted)
000000
Upgrade
Shares Change (YoY)
189.80%65.23%2.22%15.59%0.79%16.41%
Upgrade
EPS (Basic)
-14.50-29.95-127.90-237.59-243.35-174.43
Upgrade
EPS (Diluted)
-14.53-30.00-127.90-237.60-243.35-174.43
Upgrade
Free Cash Flow
-5.92-6.14-18.51-32.9-26.33-14.95
Upgrade
Free Cash Flow Per Share
-14.60-26.59-132.48-240.78-222.72-127.44
Upgrade
EBITDA
-6.15-7.46-17.62-32.84-30.17-22.34
Upgrade
D&A For EBITDA
0.10.030.040.040.040.04
Upgrade
EBIT
-6.24-7.49-17.65-32.88-30.21-22.38
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.